gptkbp:instance_of
|
gptkb:drug
|
gptkbp:bfsLayer
|
5
|
gptkbp:bfsParent
|
gptkb:Tavium
gptkb:Aubagio
|
gptkbp:activities
|
dihydroorotate dehydrogenase inhibitor
|
gptkbp:approves
|
gptkb:legislation
gptkb:2012
gptkb:United_States
|
gptkbp:availability
|
prescription only
|
gptkbp:brand
|
gptkb:Aubagio
|
gptkbp:clinical_trial
|
Phase III
long-term treatment
|
gptkbp:contraindication
|
pregnancy
severe renal impairment
severe liver impairment
|
gptkbp:developed_by
|
gptkb:Sanofi
|
gptkbp:discovered_by
|
Dr. Robert J. Fox
|
gptkbp:dosage_form
|
7 mg or 14 mg daily
|
gptkbp:excretion
|
urine
|
gptkbp:formulation
|
gptkb:tablet
|
https://www.w3.org/2000/01/rdf-schema#label
|
teriflunomide
|
gptkbp:indication
|
gptkb:relapsing_forms_of_multiple_sclerosis
|
gptkbp:ingredients
|
C12 H9 N3 O2
|
gptkbp:interacts_with
|
gptkb:warfarin
other immunosuppressants
|
gptkbp:is_atype_of
|
L04 A A18
|
gptkbp:is_monitored_by
|
blood pressure
liver function tests
complete blood count
|
gptkbp:is_used_for
|
gptkb:psychologist
|
gptkbp:lifespan
|
18 hours
|
gptkbp:manager
|
oral
|
gptkbp:marketed_as
|
gptkb:Aubagio
|
gptkbp:metabolism
|
liver
|
gptkbp:pharmacokinetics
|
highly protein-bound
immunomodulatory effects
|
gptkbp:population
|
adults
children over 10 years old
|
gptkbp:price
|
varies by region
|
gptkbp:research_areas
|
clinical trials
neurology
autoimmune diseases
pharmacology
|
gptkbp:safety_features
|
generally well tolerated
|
gptkbp:side_effect
|
fatigue
headache
nausea
hypertension
diarrhea
liver toxicity
infections
peripheral neuropathy
skin rash
hair loss
|
gptkbp:type_of
|
162401-32-3
|
gptkbp:year_created
|
gptkb:2000
|